Published: Nov, 2016
Among the branded drugs in the global erectile dysfunction drugs market, Viagra, Cialis, and Levitra have been the dominant ones for a long time. The growth rate of Viagra is decelerating due to market saturation, while Cialis is expected to maintain a favorable growth rate. Meanwhile, patent issues have created a decline in sales of Levitra/Staxyn.
According to a research report released by Transparency Market Research, the competitive intensity in the global erectile dysfunction drugs market is expected to remain fairly high. Currently, there are very few players that have established themselves as globally preferred names. At the same time, the growing number of regional players entering the market is increasing at a very fast pace, adding to the rivalry in the market.
The global erectile dysfunction drugs market is expected to drop to US$3.38 bn by the end of 2019. It is expected to be valued at US$4.90 bn by the end of 2016 owing to a few growth drivers, but is projected at a CAGR of (-8.4%) within a forecast period from 2015 to 2019.
Addition of Erectile Dysfunction Generics Deeply Hamper Global Market
Phosphodiesterase type 5 is the leading type of orally ingested drug used to combat erectile dysfunction around the world. Levitra, Cialis, and Viagra are all branded versions of oral PDE type 5 inhibitors are available and consumed in all parts of the world. “These three drugs are largely responsible for the recent profit scales in the global erectile dysfunction drugs market. However, their impending patent expiration will be a severe dent to the revenue generation capability of the market,” states a TMR analyst.
Patent loss, and the subsequent loss of brand exclusivity is expected to cut down the revenue generated by an individual drug brand in the global erectile dysfunction drugs market by 40% in the first year of its patent expiration. The reduction in revenue for each drug is expected to be set back by 30% and 20% in the years after that. The primary reason for this is the pricing of generic drugs. Due to the manufacturers of generic drugs not incurring research and development costs or spend too high on marketing, their products end up costing close to one-tenth of their branded variants, while maintaining the original drug’s efficacy.
Increasing Geriatric Demographic Could Boost ED Drug Sales
The elderly form the leading demographic to consume erectile dysfunction drugs. They are highly prone to health complications such as cardiovascular diseases, hypertension, diabetes, spinal cord injuries, and cholesterol level issues. All these problems create several other complications in the human body. In the case of men, these health issues can restrict a proper blood flow, thereby impeding the ability to maintain an erection.
The demand in the global erectile dysfunction drugs market may increase even further due to the growing consumption of drugs that include erectile dysfunction as one of their side effects. The growing consumption rate of drugs such as chlorthalidone, propanolol, diazepam, cimetidine, and naproxen are especially likely to increase the number of men suffering from ED, thereby increasing the demand for erectile dysfunction drugs in the world.
“For the manufacturers of generics, the global erectile dysfunction drugs market is close to becoming a free ground to increase profits in their key regions. At the same time, top pharma companies could look to advancing research and development to introduce novel therapies such as molecule combination and combination therapies,” adds the analyst.
The information presented in this review is based on a Transparency Market Research report, titled, “Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.”
Key segments of the Global Erectile Dysfunction Drugs Market
Global Erectile Dysfunction Drugs Market, by Branded Products:
Global Erectile Dysfunction Drugs Market, by Pipeline Drug Analysis:
Global Erectile Dysfunction Drugs Market, by Region:
- North America
- Asia Pacific
- Rest of the World
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453